ARA-290: Tissue Protective Peptide

Category: Protocols Type: Protocol Read Time: 16 minutes Author: Peptides.NYC Editorial Last Updated: 2026-05-19 URL: https://peptides.nyc/learn/ara-290-protocol

Educational content only. Not medical advice. Chronic neuropathy requires proper medical workup; consult a licensed healthcare provider.

Overview

ARA-290 (also called Cibinetide) is an 11-amino-acid synthetic peptide derived from the Helix B sequence of erythropoietin (EPO). Unlike full-length EPO, ARA-290 was engineered to activate only the tissue-protective arm of EPO signaling — the Innate Repair Receptor (IRR) — without stimulating red blood cell production.

This separation matters. Native EPO has powerful anti-inflammatory and neuroprotective effects, but chronic dosing drives polycythemia and thrombotic risk. ARA-290 was designed to preserve the repair signal and discard the erythropoietic one.

Erythropoietin-derived healing peptide. Diabetic neuropathy and chronic pain applications, innate repair receptor activation, and emerging clinical research.

ARA-290 was developed by Araim Pharmaceuticals (work originating with Brines and Cerami) and progressed through Phase 2 trials for diabetic neuropathic pain, sarcoidosis-related small fiber neuropathy, and acute respiratory distress syndrome (ARDS). Clinical development has since been discontinued for strategic and commercial reasons, though the compound is still occasionally accessed through clinical trial pathways and compounding channels.

Key Properties:

• 11-amino-acid synthetic peptide
• Derived from EPO Helix B
• Selective Innate Repair Receptor (IRR) agonist
• No erythropoietic activity
• Investigated for neuropathic pain and tissue repair

Mechanism of Action

ARA-290 works through a receptor distinct from the classical EPO receptor (EPOR) homodimer that drives red blood cell production.

1. IRR binding - Selectively engages the Innate Repair Receptor, a heterodimer of EPOR and the β-common receptor (CD131)
2. No EPOR homodimer activation - Avoids the receptor configuration responsible for erythropoiesis
3. Anti-inflammatory signaling - Downregulates cytokine cascades in injured tissue
4. Neuroprotective effects - Supports neuronal survival and small fiber repair
5. Tissue protection - Modulates ischemic and inflammatory injury responses across multiple organ systems

The clean separation between EPOR-driven erythropoiesis and IRR-driven repair is the core innovation behind ARA-290.

Why Separating From EPO Matters

This is the central rationale for ARA-290 — and the reason a derivative peptide exists at all.

Full EPO problems with chronic use:

• Elevated hemoglobin and hematocrit (polycythemia)
• Increased blood viscosity
• Thrombotic and cardiovascular risk
• Limits chronic anti-inflammatory dosing

ARA-290 solution:

• Retains tissue-protective and anti-inflammatory benefits
• No measurable change in hemoglobin in trials
• No documented thrombotic signal
• Theoretically safer for long-term, repeat dosing

The work of Anthony Cerami and Michael Brines established that EPO's protective effects could be molecularly decoupled from its hematologic effects. ARA-290 is the most clinically advanced product of that line of research.

Clinical Trial History

ARA-290 progressed through several Phase 2 programs under Akeso/Araim Pharmaceuticals.

Diabetic Peripheral Neuropathy

• Multiple Phase 2 trials in painful diabetic neuropathy
• Modest but real reductions in neuropathic pain scores
• Some evidence of small fiber regeneration on skin biopsy

Sarcoidosis-Related Small Fiber Neuropathy

• Positive Phase 2 signal in this niche population
• Work led in part by researchers including Niesters and colleagues
• Improvements in pain and quality of life measures

ARDS / COVID-19 Era

• Investigated as anti-inflammatory adjunct in severe lung injury
• Mechanistic rationale around innate repair signaling
• Limited late-phase follow-through

Clinical development was ultimately discontinued, reportedly for a mix of strategic, commercial, and effect-size reasons rather than safety. The compound is sometimes still accessed via investigator-initiated studies or specialty compounding for off-label use under physician oversight.

Conditions Researched

ARA-290 has been studied or hypothesized for:

Diabetic Peripheral Neuropathy

• Chronic burning, tingling, and pain in feet and legs
• Primary indication in pivotal Phase 2 work
• Modest pain reduction documented

Sarcoidosis-Related Small Fiber Neuropathy

• Autoimmune-driven nerve damage
• Stronger signal than diabetic indication
• Quality of life improvements reported

ARDS and COVID-19 Lung Injury

• Anti-inflammatory mechanism in acute injury
• Exploratory use during pandemic

Traumatic Nerve Injury

• Theoretical application based on IRR repair signaling
• Limited human data

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

• Emerging interest given mechanism
• Preclinical and early clinical exploration

Dosing Protocols

Administration Notes:

• Subcutaneous injection is the standard route
• Abdomen or thigh rotation typical
• Insulin syringes (29-31 gauge) adequate
• Reconstitute with bacteriostatic water per vial concentration

Clinical-trial doses are notably higher than the milligram doses seen with many other research peptides. Plan vial sizing accordingly.

Expected Outcomes

Based on Phase 2 data and reported user experience:

Weeks 1-2:

• Subtle changes in neuropathic pain quality
• Possible reduction in burning or shooting sensations
• Generally well tolerated from first dose

Weeks 2-8:

• Measurable reductions in pain scores in responders
• Improved sleep where pain disrupts sleep
• Sarcoidosis-neuropathy patients tended to respond more clearly than diabetic patients

Beyond Initial Course:

• Some trial data suggested measurable small fiber regeneration on skin biopsy
• Tissue healing applications outside neuropathy remain largely theoretical

Be honest with expectations: in published trials, ARA-290 produced statistically meaningful but clinically modest effects — not transformative pain elimination.

Side Effects & Safety

ARA-290 was exceptionally well-tolerated in Phase 2 trials — arguably its strongest clinical attribute and a meaningful advantage over native EPO.

Reported Effects:

• Occasional injection site reactions (mild)
• Headache (uncommon)
• Fatigue (uncommon)

Notably Absent:

• No thrombotic events documented in trial populations
• No clinically significant hemoglobin or hematocrit elevation
• No clear cardiovascular signal

Contraindications:

• Active malignancy (theoretical concern with repair signaling)
• Pregnancy and breastfeeding (not studied)
• Children (not studied)
• Active thromboembolic disease (precautionary, despite clean trial data)

The safety profile is one of the cleanest in the EPO-derived peptide space. The honest limitation is efficacy, not tolerability.

Stacking

ARA-290 stacks are largely theoretical given limited human data, but the mechanism suggests rational combinations.

ARA-290 + BPC-157

• Tissue repair synergy across multiple compartments
• BPC-157 angiogenesis complements IRR-driven repair signaling
• Consider for traumatic nerve injury contexts

ARA-290 + TB-500

• Nerve regeneration emphasis
• TB-500 supports cell migration and axonal repair
• Reasonable pairing for stubborn peripheral neuropathy

ARA-290 + Thymosin Alpha-1

• Useful where immune-mediated nerve inflammation is a driver
• Sarcoidosis-related neuropathy is the conceptual fit
• Discuss with a physician familiar with both compounds

ARA-290 + Conventional Neuropathy Care

• Does not replace gabapentin, pregabalin, duloxetine, or topical agents
• May serve as a mechanism-distinct adjunct
• Coordinate with your prescribing clinician

Limitations

This is the section to read twice.

ARA-290 trials produced modest, not transformative, effects. The mechanism is interesting. The safety profile is excellent. But the magnitude of clinical benefit in diabetic neuropathy was small enough that the development program did not advance to pivotal Phase 3 in that indication.

Key honest points:

• Pain reductions were statistically significant but modest in absolute terms
• Sarcoidosis neuropathy showed the strongest signal — a niche, not a mass-market win
• Small fiber regeneration on biopsy is encouraging but did not translate to large symptomatic gains
• Clinical development discontinuation reflects, in part, an effect-size problem
• Any non-neuropathy "tissue protection" application is currently extrapolation, not evidence

ARA-290 is a clean, mechanistically elegant peptide. It is not a miracle compound.

Cycling

Clinical exposure has primarily been studied as discrete 28-day courses.

Reasonable Patterns:

• Standard course: 4 mg SC daily for 28 days
• Washout: 4-8 weeks off
• Repeat course: Based on response and clinician guidance
• Maintenance: No well-established maintenance regimen in trial data

Wellness-style chronic micro-dosing is essentially uncharacterized. The conservative approach is to mirror the trial structure rather than improvise indefinite low-dose use.

Quality Considerations

What to Look For:

• Third-party COA with HPLC and mass spectrometry
• Purity >98%
• Lyophilized white powder
• Reputable research-peptide supplier or licensed compounding pharmacy

Red Flags:

• Pre-mixed solutions
• No documentation of identity testing
• Suspiciously low pricing for an 11-amino-acid peptide at clinical doses
• Vendors unable to discuss reconstitution at clinical-dose scales

Frequently Asked Questions

Q: Does ARA-290 actually relieve neuropathy pain? A: In Phase 2 trials, yes — modestly. Reductions in pain scores were real and statistically meaningful, but not transformative. Sarcoidosis-related small fiber neuropathy showed the strongest signal; diabetic neuropathy response was more variable.

Q: How does ARA-290 compare to gabapentin? A: They are not the same category of intervention. Gabapentin is a symptomatic neuropathic pain treatment that works on calcium channel subunits. ARA-290 is mechanism-targeted at tissue repair and inflammation. ARA-290 may be considered as an adjunct, not a replacement.

Q: Can I stack ARA-290 with BPC-157 for nerve injury? A: The mechanisms are complementary (IRR-mediated repair plus BPC-157's broad tissue effects), and the stack is commonly discussed for peripheral nerve injury. Human evidence for the combination specifically is anecdotal.

Q: How do I source authentic ARA-290? A: This is harder than for more common research peptides. Clinical-grade material has historically been trial-restricted. Some specialty compounding pharmacies prepare it for physician-directed off-label use. Demand full COA documentation regardless of source.

Q: Is ARA-290 useful for long COVID? A: It was investigated for ARDS during the pandemic, and the mechanism is plausible for inflammation-driven post-viral syndromes. Direct long COVID trial data is limited. Treat any such use as exploratory.

Q: What does ARA-290 cost? A: Pricing varies widely. Because clinical dosing is in the 4-8 mg/day range — far higher than most peptides — a full 28-day course requires substantially more material and is meaningfully more expensive than typical peptide protocols.

Q: Is ARA-290 FDA-approved? A: No. Clinical development was discontinued before approval in any indication. It remains a research compound and is sometimes accessed via compounding or clinical trial pathways.

Q: Does ARA-290 affect red blood cell counts like EPO? A: No. That is the entire engineering rationale. Trials consistently showed no clinically significant change in hemoglobin or hematocrit — distinguishing it sharply from native EPO.

Related Content

• BPC-157 Complete Guide
• TB-500 Complete Guide
• Cerebrolysin Protocol
• Reconstitution Cheat Sheet
• Compounding Pharmacy Guide

Disclaimer: This content is for educational purposes only and is not medical advice. ARA-290 (Cibinetide) is not FDA-approved; clinical development has been discontinued in its primary indications. It is a research compound that may be accessed in limited cases through clinical trials or specialty compounding under physician direction. Chronic neuropathy requires a proper medical workup. Consult a licensed healthcare provider before considering any peptide protocol.

Source: https://peptides.nyc/learn/ara-290-protocol